Biotech Portfolio Battle: Axsome Therapeutics Versus Moderna Outlook for 2027

Market participants looking at long-term pharmaceutical holdings are contrasting the financial metrics and risk profiles of Axsome Therapeutics and Moderna. Axsome concentrates on central nervous system conditions, offering therapies for major depressive disorder, migraines, and excessive daytime sleepiness. Meanwhile, Moderna relies on its messenger RNA platform, attempting to scale past pandemic-era products into oncology treatments and broader respiratory vaccines.

Financial Trajectories and Balance Sheets

For the twelve months ending September 30, 2026, Axsome generated approximately $865.3 million in revenue, marking a 54% increase compared to the prior period. The firm posted a net loss of about $157.3 million, resulting in a negative net margin of 18.2%. Its balance sheet from December 2025 indicated a debt-to-equity ratio of roughly 2.7x, a current ratio of 1.6x, and a free cash flow of negative $93.9 million for the 2025 fiscal year.

In contrast, Moderna reported revenue of approximately $2.5 billion for the twelve months ending September 30, 2026, reflecting 13.7% growth. The company registered a substantially larger net loss of about $2.8 billion, leading to a negative net margin of 110.5% due to heavy research and development spending. Moderna's balance sheet showed a lower debt-to-equity ratio of 0.2x, a strong current ratio of 3.3x, and free cash flow of roughly negative $2.1 billion for the 2025 fiscal year.

Operational Risks and Competition

Both enterprises face distinct operational hurdles. Axsome deals with competitive pressures from generic manufacturers and major pharmaceutical firms, relies heavily on third-party vendors for production, and maintains strict loan covenants with Blackstone. Moderna contends with established giants like Pfizer, Sanofi, and GSK, navigates regulatory uncertainty regarding vaccine demand, and depends on complex cold-chain logistics alongside ongoing intellectual property litigation.

What to watch next: Monitor upcoming clinical trial milestones and quarterly revenue growth figures to gauge how effectively both companies manage their burn rates.